Browse TBXAS1

Summary
SymbolTBXAS1
Namethromboxane A synthase 1 (platelet)
Aliases CYP5; CYP5A1; TXS; TXAS; cytochrome P450, family 5, subfamily A, polypeptide 1; thromboxane A synthase 1 (pl ......
Chromosomal Location7q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Multi-pass membrane protein
Domain PF00067 Cytochrome P450
Function

-

> Gene Ontology
 
Biological Process GO:0001516 prostaglandin biosynthetic process
GO:0001676 long-chain fatty acid metabolic process
GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006636 unsaturated fatty acid biosynthetic process
GO:0006690 icosanoid metabolic process
GO:0006692 prostanoid metabolic process
GO:0006693 prostaglandin metabolic process
GO:0016053 organic acid biosynthetic process
GO:0019369 arachidonic acid metabolic process
GO:0019371 cyclooxygenase pathway
GO:0033559 unsaturated fatty acid metabolic process
GO:0044283 small molecule biosynthetic process
GO:0046394 carboxylic acid biosynthetic process
GO:0046456 icosanoid biosynthetic process
GO:0046457 prostanoid biosynthetic process
GO:0072330 monocarboxylic acid biosynthetic process
Molecular Function GO:0004497 monooxygenase activity
GO:0004796 thromboxane-A synthase activity
GO:0005506 iron ion binding
GO:0016627 oxidoreductase activity, acting on the CH-CH group of donors
GO:0016628 oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
GO:0016853 isomerase activity
GO:0016860 intramolecular oxidoreductase activity
GO:0020037 heme binding
GO:0036134 12-hydroxyheptadecatrienoic acid synthase activity
GO:0046906 tetrapyrrole binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04611 Platelet activation
hsa00590 Arachidonic acid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-2142753: Arachidonic acid metabolism
R-HSA-211859: Biological oxidations
R-HSA-211897: Cytochrome P450 - arranged by substrate type
R-HSA-211979: Eicosanoids
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-211945: Phase 1 - Functionalization of compounds
R-HSA-2162123: Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
Summary
SymbolTBXAS1
Namethromboxane A synthase 1 (platelet)
Aliases CYP5; CYP5A1; TXS; TXAS; cytochrome P450, family 5, subfamily A, polypeptide 1; thromboxane A synthase 1 (pl ......
Chromosomal Location7q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TBXAS1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTBXAS1
Namethromboxane A synthase 1 (platelet)
Aliases CYP5; CYP5A1; TXS; TXAS; cytochrome P450, family 5, subfamily A, polypeptide 1; thromboxane A synthase 1 (pl ......
Chromosomal Location7q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TBXAS1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.5 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTBXAS1
Namethromboxane A synthase 1 (platelet)
Aliases CYP5; CYP5A1; TXS; TXAS; cytochrome P450, family 5, subfamily A, polypeptide 1; thromboxane A synthase 1 (pl ......
Chromosomal Location7q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TBXAS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3150.458
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4040.806
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2570.847
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2740.529
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8630.634
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4680.834
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2270.597
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3590.775
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1710.909
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8530.581
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.010.678
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3590.02
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TBXAS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTBXAS1
Namethromboxane A synthase 1 (platelet)
Aliases CYP5; CYP5A1; TXS; TXAS; cytochrome P450, family 5, subfamily A, polypeptide 1; thromboxane A synthase 1 (pl ......
Chromosomal Location7q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TBXAS1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTBXAS1
Namethromboxane A synthase 1 (platelet)
Aliases CYP5; CYP5A1; TXS; TXAS; cytochrome P450, family 5, subfamily A, polypeptide 1; thromboxane A synthase 1 (pl ......
Chromosomal Location7q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TBXAS1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TBXAS1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTBXAS1
Namethromboxane A synthase 1 (platelet)
Aliases CYP5; CYP5A1; TXS; TXAS; cytochrome P450, family 5, subfamily A, polypeptide 1; thromboxane A synthase 1 (pl ......
Chromosomal Location7q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TBXAS1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTBXAS1
Namethromboxane A synthase 1 (platelet)
Aliases CYP5; CYP5A1; TXS; TXAS; cytochrome P450, family 5, subfamily A, polypeptide 1; thromboxane A synthase 1 (pl ......
Chromosomal Location7q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TBXAS1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTBXAS1
Namethromboxane A synthase 1 (platelet)
Aliases CYP5; CYP5A1; TXS; TXAS; cytochrome P450, family 5, subfamily A, polypeptide 1; thromboxane A synthase 1 (pl ......
Chromosomal Location7q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TBXAS1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTBXAS1
Namethromboxane A synthase 1 (platelet)
Aliases CYP5; CYP5A1; TXS; TXAS; cytochrome P450, family 5, subfamily A, polypeptide 1; thromboxane A synthase 1 (pl ......
Chromosomal Location7q34-q35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TBXAS1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TBXAS1.
ID Name Drug Type Targets #Targets
DB00795SulfasalazineSmall MoleculeACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC7A11, ......10
DB01207RidogrelSmall MoleculeTBXA2R, TBXAS12
DB03052DazoxibenSmall MoleculeTBXAS11
DB05505NM-702Small MoleculeTBXAS11